Clearmind Medicine
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Clearmind Medicine generated cash of -$4,556,543, which is more than the previous year. Cash used in financing activities reached the amount of $8,434,430 last year. Net change in cash is therefore $3,831,636.
Cash Flow
| 2017 | -9.12K | -18.42K | 130K |
|---|---|---|---|
| 2018 | -105.58K | -131.17K | 208K |
| 2019 | -63.00K | -10K | 0 |
| 2020 | -264.45K | -5.09K | 598.7K |
| 2021 | -2.83M | -251.18K | 7.35M |
| 2022 | -5.08M | -7.59K | 698.40K |
| 2023 | -4.55M | -18.96K | 8.43M |
CMND Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 93.54K | 4.59M | 329.84K | 688 | 73.69K | 102.45K | 0 |
Operating activities | |||||||
Net income | -6.23M | -9.41M | -3.89M | -233.22K | -105.28K | -194.53K | -6.67K |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 41.58K | 113.37K | 2.57K | 0 | 0 | 0 | 0 |
Stock-based compensation expense | 264.94K | 887.29K | 500.23K | 0 | 0 | 0 | 0 |
| Deferred income tax benefit | 264.94K | 887.29K | 500.23K | 0 | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | -151.48K | 27.21K | -157.74K | -28 | 5.35K | 0 | -371 |
Inventories | 151.48K | -27.21K | 157.74K | 28 | -5.35K | 0 | 0 |
Accounts payable | -450.66K | 1.24M | 343.59K | -7.44K | 5.09K | 6.57K | 0 |
Cash generated by operating activities | -4.55M | -5.08M | -2.83M | -264.45K | -63.00K | -105.58K | -9.12K |
Investing activities | |||||||
Purchases Of Investments | 0 | 0 | -20K | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | -7.59K | -231.18K | -10K | -10K | -131.17K | -18.42K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -18.96K | -7.59K | -251.18K | -5.09K | -10K | -131.17K | -18.42K |
Financing activities | |||||||
Common Stock Issued | 8.03M | 428.05K | 7.72M | 650K | 0 | 210K | 130K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -29.59K | -96 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 8.43M | 698.40K | 7.35M | 598.7K | 0 | 208K | 130K |
Net Change In Cash | 3.83M | -4.42M | 4.28M | 329.15K | -73.00K | -28.76K | 102.45K |
Cash at end of period | 3.92M | 175.76K | 4.61M | 329.84K | 688 | 73.69K | 102.45K |
| Data source | Data source |